BIMEKIZUMAB IN BDMARD-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: IMPROVEMENTS IN PSARC OVER 24 WEEKS IN THE PHASE 3 BE OPTIMAL TRIAL

被引：0
|
作者：
McInnes, Iain [1 ]
Ink, Barbara [2 ]
Bajracharya, Rajan [2 ]
Taieb, Vanessa [3 ]
Tillett, William R. [4 ]
机构：
[1] Univ Glasgow, IBM Coll Med Vet & Life Sci, Glasgow, Scotland
[2] UCB Pharma, Rheumatol, Slough, England
[3] UCB Pharma, Rheumatol, Colombes, France
[4] Univ Bath, Royal Natl Hosp Rheumat Dis, Dept Life Sci, Bath, England
来源：
RHEUMATOLOGY | 2023年 / 62卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P171
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Early Onset of Efficacy with Apremilast Monotherapy in Biologic-Naive Patients with Active Psoriatic Arthritis: A Phase IIIb, Randomized, Controlled Trial
    Nash, Peter
    Ohson, Kamal
    Walsh, Jessica
    Delev, Nikolay
    Nguyen, Dianne
    Teng, Lichen
    Gomez-Reino, Juan J.
    Aelion, Jacob A.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [42] Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naive or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Placebo-Controlled Studies
    Husni, M. Elaine
    Mease, Philip J.
    Merola, Joseph
    Behrens, Frank
    Favalli, Ennio Giulio
    McGonagle, Dennis
    Tillett, William
    Tsuji, Shigeyoshi
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Coarse, Jason
    Lambert, Jeremy
    Gossec, Laure
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4197 - 4199
  • [43] BIMEKIZUMAB TREATMENT RESULTED IN IMPROVEMENTS IN FATIGUE AND PAIN IN BIOLOGIC DMARD-NAIVE OR TNFI-IR PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: POOLED 16-WEEK RESULTS FROM TWO PHASE 3 RANDOMISED, PLACEBO-CONTROLLED STUDIES
    Rischmueller, Maureen
    Husni, M. Elaine
    Mease, Philip J.
    Merola, Joseph F.
    Behrens, Frank
    Favalli, Ennio G.
    McGonagle, Dennis
    Tillett, William
    Tsuji, Shigeyoshi
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Coarse, Jason
    Lambert, Jeremy
    Gossec, Laure
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 26 - 26
  • [44] PSYCHOMETRIC ASSESSMENT OF THE PSORIATIC ARTHRITIS IMPACT OF DISEASE-12 (PSAID-12) QUESTIONNAIRE USING POOLED DATA FROM THE PHASE 3 BE OPTIMAL AND BE COMPLETE TRIALS OF BIMEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS
    Gossec, L.
    Coates, L. C.
    Orbai, A. M.
    Pelligra, C.
    Lambert, J.
    Ciaravino, V
    Ink, B.
    Taieb, V
    Gladman, D. D.
    VALUE IN HEALTH, 2023, 26 (06) : S323 - S323
  • [45] Bimekizumab Treatment Impact on Work Productivity in Biologic DMARD-Naive and TNFi-IR Patients with Active Psoriatic Arthritis: Results up to 1 Year from Two Phase 3 Studies
    Mease, Philip J.
    Gladman, Dafna
    Gossec, Laure
    Nash, Peter
    Ink, Barbara
    Coarse, Jason
    Lyris, Nikos
    Willems, Damon
    Tillett, William R.
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2774 - 2777
  • [46] BIMEKIZUMAB TREATMENT RESULTED IN CLINICALLY MEANINGFUL IMPROVEMENTS IN THE PSORIATIC ARTHRITIS IMPACT OF DISEASE-12 (PSAID-12) SCORES USING POOLED RESULTS FROM TWO PHASE 3 TRIALS IN PATIENTS WITH PSORIATIC ARTHRITIS
    Gossec, L.
    Coates, L.
    Orbai, A. M.
    De Wit, M.
    Lambert, J.
    Ink, B.
    Taieb, V.
    Gladman, D. D.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1130 - 1130
  • [47] ASSESSMENT OF PAIN OUTCOMES IN A PHASE 2 TRIAL OF DEUCRAVACITINIB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
    Mease, P. J.
    Eder, L.
    Ogdie-Beatty, A.
    Deodhar, A.
    Banerjee, S.
    Nowak, M.
    Choi, J.
    Lehman, T.
    Strand, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1132 - 1133
  • [48] Ixekizumab Provides Improvements through 52 Weeks in Physical Function, Quality of Life, and Work Productivity in Biologic DiseaseModifying Antirheumatic Drug-Naive Patients with Active Psoriatic Arthritis
    Gottlieb, Alice
    Husni, Elaine
    Shuler, Catherine
    Burge, Russel
    Lin, Chen-Yen
    Lee, Chin
    Gladman, Dafna
    JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 924 - 925
  • [49] The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial
    Strand, Vibeke
    Kaeley, Gurjit S.
    Bergman, Martin J.
    Gladman, Dafna D.
    Coates, Laura C.
    Sherif, Bintu
    Hur, Peter
    Parikh, Bhumik
    Gilloteau, Isabelle
    Mease, Philip J.
    LANCET RHEUMATOLOGY, 2022, 4 (03): : E208 - E219
  • [50] Apremilast in the Treatment of DMARD-Naive Psoriatic Arthritis Patients: Results of a Phase 3 Randomized, Controlled Trial (PALACE 4)
    Wells, Alvin F.
    Edwards, Christopher J.
    Adebajo, Adewale O.
    Kivitz, Alan J.
    Bird, Paul
    Shah, Kamal
    Hu, ChiaChi
    Stevens, Randall M.
    Aelion, Jacob A.
    ARTHRITIS AND RHEUMATISM, 2013, 65 (12): : 3320 - 3321
12345